Invivyd Inc
IVVD
|
$2.295
-2.34%
-2.4%
1.1M
|
Manufacturing
(0.0% 1d) (-22.0% 1m) (108.4% 1y) (0.0% 2d) (0.0% 3d) (-11.7% 7d) (7.6% volume)
Earnings Calendar:
Market Cap: $ 273,612,723
https://adagiotx.com
Sec Filling | Patents | 2021 employees
Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch.
optical security
add to watch list Paper trade email alert is off
Press-releases
Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
IVVD | $2.295 -2.34% -2.4% 1.1M
|
Manufacturing
|
| O: -2.63%
H: 1.69%
C: -5.07%
services system for
Invivyd Announces CEO Transition
Published: 2024-04-12 (Crawled : 12:00) - globenewswire.com
IVVD | $2.295 -2.34% -2.4% 1.1M
|
Manufacturing
|
| O: 1.16%
H: 0.0%
C: 0.0%
ceo
Invivyd Announces CEO TransitionJeremy Gowler appointed Interim CEO
Published: 2024-04-12 (Crawled : 13:30) - biospace.com/
IVVD | $2.295 -2.34% -2.4% 1.1M
|
Manufacturing
|
| O: 1.16%
H: 0.0%
C: 0.0%
ceo
Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million
Published: 2024-04-04 (Crawled : 20:00) - globenewswire.com
IVVD | $2.295 -2.34% -2.4% 1.1M
|
Manufacturing
|
| O: 5.31%
H: 4.24%
C: -12.47%
million revenue update
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
Published: 2024-03-28 (Crawled : 11:00) - globenewswire.com
IVVD | $2.295 -2.34% -2.4% 1.1M
|
Manufacturing
|
| O: -1.0%
H: 15.15%
C: 12.12%
business year financial results
Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial
Published: 2024-03-22 (Crawled : 20:00) - globenewswire.com
IVVD | $2.295 -2.34% -2.4% 1.1M
|
Manufacturing
| Email alert
Add to watchlist
vyd222 trial
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
Published: 2024-03-22 (Crawled : 19:00) - globenewswire.com
IVVD | $2.295 -2.34% -2.4% 1.1M
|
Manufacturing
| Email alert
Add to watchlist
vyd222 covid-19 fda authorization
Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Published: 2024-02-05 (Crawled : 21:00) - globenewswire.com
IVVD | $2.295 -2.34% -2.4% 1.1M
|
Manufacturing
|
| O: -1.22%
H: 3.2%
C: 0.62%
conference
Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents
Published: 2024-01-03 (Crawled : 12:00) - globenewswire.com
IVVD | $2.295 -2.34% -2.4% 1.1M
|
Manufacturing
|
| O: 3.56%
H: 3.44%
C: -0.53%
vyd222 covid-19 fda authorization
Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19
Published: 2023-12-18 (Crawled : 12:00) - globenewswire.com
IVVD | $2.295 -2.34% -2.4% 1.1M
|
Manufacturing
|
| O: 23.93%
H: 133.17%
C: 77.72%
vyd222 covid-19 positive ongoing trial results
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10